Market capitalization | $25.46m |
Enterprise Value | $5.64m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.73 |
P/S ratio (TTM) P/S ratio | 3.28 |
P/B ratio (TTM) P/B ratio | 1.33 |
Revenue growth (TTM) Revenue growth | 14,014.81% |
Revenue (TTM) Revenue | $7.76m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Lipocine, Inc. forecast:
2 Analysts have issued a Lipocine, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 7.76 7.76 |
15,420%
15,420%
|
|
Gross Profit | 7.73 7.73 |
25,667%
25,667%
|
|
EBITDA | -5.42 -5.42 |
63%
63%
|
EBIT (Operating Income) EBIT | -5.46 -5.46 |
63%
63%
|
Net Profit | -4.06 -4.06 |
75%
75%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Mahesh Patel |
Employees | 17 |
Founded | 2011 |
Website | www.lipocine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.